All relevant data are within the paper and its Supporting Information files.

Introduction {#sec006}
============

Heart failure is a consequence of structural and functional impairments of ventricular myocardium that reduce the ability of the heart to adequately supply blood to the body \[[@pone.0221519.ref001]\]. The current method of classifying heart failure is by whether left ventricular ejection fraction (LVEF) is reduced ("HFrEF") or relatively preserved ("HFpEF), which generally subdivides heart failure into respective categories that respond to multiple types of drug or device therapies vs. those that do not \[[@pone.0221519.ref002]\]. Despite the established effectiveness of 8 drug and 2 device classes \[[@pone.0221519.ref003]\], HFrEF continues to increase in prevalence \[[@pone.0221519.ref004]\] and major adverse outcomes including mortality have not appreciably declined \[[@pone.0221519.ref005]\].

Current drug therapy of HFrEF is based on targeting final common pathway maladaptive mechanisms that provide short term compensation to impaired ventricular chamber contractile function, but have adverse effects long term \[[@pone.0221519.ref003]\]. Despite the relative success of this therapeutic approach, the molecular mechanisms underlying the progression of HFrEF as well as the molecular phenotypic signatures of effective therapies have not been established. Reduced to first principles, disease in any tissue is the result of altered gene expression that produces organ dysfunction, and therefore the causative mechanisms are discoverable by identifying abnormal patterns of gene expression directly related to the dysfunction. In HFrEF we have attempted to identify abnormal gene expression profiles at the mRNA \[[@pone.0221519.ref006]--[@pone.0221519.ref008]\] or miRNA \[[@pone.0221519.ref009]\] level by producing therapeutic interventional reversal of the structural and functional abnormalities in HFrEF ventricles, and identifying ventricular septal endomyocardial biopsy gene expression changes associated with dynamic left ventricular reverse remodeling. This approach, which we term "sequential analysis of myocardial gene expression with phenotypic change" (SAMGE-PC), has several potential advantages, including: investigating serial changes in subjects whose genetic and non-interventional therapeutic backgrounds remain constant before and after ventricular reverse remodeling; being able to link changes in gene expression to specific functional and structural changes in ventricular myocardium; having an internal control group consisting of reverse remodeling nonresponders; being able to investigate HFrEF at earlier stages than can be done by using starting material from explanted hearts removed from cardiac transplant recipients; and the inherent statistical advantage of within group repeated measures vs. cross-sectional comparisons \[[@pone.0221519.ref007]\].

In these studies, for mRNA expression we have used two types of quantitative PCR \[[@pone.0221519.ref006],[@pone.0221519.ref008],[@pone.0221519.ref009]\], two generations of microarrays \[[@pone.0221519.ref007]--[@pone.0221519.ref009]\] and most recently, RNA-Sequencing (RNA-Seq) \[[@pone.0221519.ref010]\]. Each of these three methodologies has been widely used for quantifying mRNA expression, and all have undergone extensive validation, typically in "cross-platform" analyses ([11]{.ul}--[13]{.ul}). However, the inherent methodological differences in these platforms as well as limitations in starting material means that in sampling human tissue *in situ* platform agreement may be lower than in model systems \[[@pone.0221519.ref014],[@pone.0221519.ref015]\]. Using a repeated measures longitudinal design helps counter these limitations \[[@pone.0221519.ref016]\], as does the use of a restricted candidate module with fewer genes and higher probability of change, but these may not be adequate to address inherent methodological challenges. Another design feature with the potential to improve reproducibility and reduce false discovery is the deployment of multiple platforms in contemporaneous measurements, allowing for cross-platform validation \[[@pone.0221519.ref017]--[@pone.0221519.ref019]\]. The primary aim of the current report was to investigate the utility of cross-platform validation of gene expression changes in the setting of a SAMGE-PC study, with a secondary aim of evaluating the effects of downsizing sample size into a greater phenotypic change cohort.

Materials and methods {#sec007}
=====================

Study material and datasets {#sec008}
---------------------------

### Clinical study {#sec009}

The data are derived from the [B]{.ul}eta-blocker Effect [O]{.ul}n [R]{.ul}emodeling and [G]{.ul}ene Expression study ("BORG", NCT01798992), the full design of which is described elsewhere \[[@pone.0221519.ref008]\]. Briefly, eligible idiopathic dilated cardiomyopathy (IDC) patients with HFrEF (LVEF ≤40%, symptomatic heart failure) were treated with one of three combinations of β-adrenergic receptor (AR) antagonists that had β~1~-AR blockade in common \[[@pone.0221519.ref008]\]. RV distal septal endomyocardial biopsies were performed prior to and after 3 and 12 months treatment with these regimens as previously described \[[@pone.0221519.ref008]\]. In the current analysis the 12 month results are used unless data were unavailable (n = 8), in which case 3 month data were used by last observation carried forward (LOCF) \[[@pone.0221519.ref008]\]. The primary method of measuring LV remodeling was by ejection fraction (EF, a measure of chamber structure and function \[[@pone.0221519.ref003]\]) by radionuclide SPECT imaging \[[@pone.0221519.ref003],[@pone.0221519.ref008]\] for determination of LVEF or RVEF. All patients signed written consent for this multi-center study, which was conducted at the University of Colorado Anschutz Medical Campus and the University of Utah Medical Center and approved by the Institutional Review Boards at both sites. The study was conducted according to the Declaration of Helsinki and included a Data and Safety Monitoring Board.

### RNA extraction and mRNA abundance measurements {#sec010}

RNA extraction was performed on RV distal septum endomyocardial biopsy samples as previously described \[[@pone.0221519.ref008]\]. All mRNA measurements were from the same RNA extraction, typically involving 2--5 separate biopsy samples from an individual patient. Extracted RNA was stored at -80°C until use. Gene expression measurements were conducted by 3 platforms: TaqMan RT-qPCR (for 50 candidate genes) \[[@pone.0221519.ref008]\]; microarray (for global as well as candidate gene expression); and RNA-Seq (global and candidate gene expression). Candidate genes were selected for the likelihood they may mediate myocardial remodeling in response to neurohormonal activation or inhibition, within paradigms of either fetal/adult expression patterns, β~1~-adrenergic receptor signaling or thyroid hormone mediated effects \[[@pone.0221519.ref008]\]. RT-qPCR and microarray analyses were performed as previously described \[[@pone.0221519.ref008]\]. The microarray method was the Affymetrix HG-U133 Plus 2.0 Microarray that contains sequences for 22,963 separate gene sequences, with which 19,672 separate mRNAs were identified, including for all 50 of the candidate genes. RNA-Seq was conducted as previously described \[[@pone.0221519.ref010]\], using an Illumina HiSeq2500 platform and ribosome depleted RNA. RNA-Seq identified 15,366 separate gene transcripts, including the 50 candidate genes. RT-qPCR Ct values were normalized to GAPDH gene expression. Normalized changes in RT-qPCR gene expression from baseline to LOCF were calculated with the ddCt~.~ method as previously described \[[@pone.0221519.ref008]\]. Microarray gene expression data were normalized by log-scale robust multi-microarray analysis. RNA-Seq data transcript levels were quantified as fragments per kilobase of exon per million mapped reads (FPKM) as previously described \[[@pone.0221519.ref010]\].

### Patient cohorts and reverse remodeling phenotypic groups {#sec011}

Two patient cohorts were analyzed: the BORG IDC cohort of 47 subjects, ("*All-Subjects"* (*A-S*)); and an *A-S* derived subcohort of the largest degree of reverse remodeling responders and control nonresponders ("*Super-Responder"* restricted *(S-R)* cohort). The 3 LV phenotypes as defined by their LVEF change measured at LOCF are therefore Responders (R) and Nonresponders (NR) in the *A-S* cohort, and Super-Responders (SR) in the *S-R* cohort. SRs have their own NR analysis group, which is the same phenotype as *A-S* NRs.

[*A-S* Cohort.]{.ul} This IDC cohort consisted of 31 reverse remodeling Responders (R, n = 31) defined by an LOCF increase in LVEF of ≥5 absolute % at 3 months or 8% at 12 months, and 16 Nonresponders (NR) \[[@pone.0221519.ref008]\]. In R the baseline LVEF/RVEFs in %±SD were 25.6± 8.2/27.0± 8.7, and in NR 27.8± 9.9/28.2/9.5 (R vs. NR P = 0.42 in LVEF, 0.71 in RVEF). The LOCF---baseline absolute % increase in LVEF (mean±SEM) was 21.2±1.8 in R, vs. 0.9±1.1% in NR (P \<0.0001). The absolute % change in RVEF was 9.7±2.2 in R, vs. 5.2±3.8 in NR (P = 0.30).

[*S-R* Cohort]{.ul}. In this cohort "Super Responders" (SR, n = 6) were defined by an increase in LVEF of ≥10 absolute % (mean±SEM increase by 31±4%, P = 0.035 vs. *A-S* cohort R), and NRs (n = 6) by age and gender-matched patients with no LVEF increase ≥5% (mean change 0±2%, P \<0.0001 vs. R). The mean±SD baseline and LOCF LVEFs in the *S-R* cohort were respectively 32± 9% and 32±8% in NR, and 24±7% (P = 0.63 vs. *A-S* R baseline) and 53±6% (P \<0.001 vs. *A-S* R LOCF) in SR. RVEF mean change±SEM in SR was 16.4±8.1%, vs. 7.5±6.7% in NR (P = 0.42).

### Summary of gene analysis groups, platforms and patient cohorts {#sec012}

[Fig 1](#pone.0221519.g001){ref-type="fig"} summarizes the platforms, patient cohorts, reverse remodeling phenotypes and types of gene expression analyses (candidate or global) investigated. A data table roadmap is given in the Supporting Information ([S1 Table](#pone.0221519.s003){ref-type="supplementary-material"}).

![Summary of LVEF changes from baseline.\
LVEF change from baseline in the 47 patients comprising the All-Subjects (*A-S*) Cohort, and the 12 Subjects in the Super-Responder (*S-R*) subcohort. Messenger RNA measurement platforms, Responder/Nonresponder reverse remodeling phenotype and types of gene expression changes measured in each platform are also given.](pone.0221519.g001){#pone.0221519.g001}

Data analyses {#sec013}
-------------

### Data analysis within reverse remodeling groups {#sec014}

Changes in gene expression measured as mRNA abundance were assessed within R, SR or NR reverse remodeling groups as change from baseline, using paired analyses of baseline vs. LOCF values of dCt for RT-qPCR, fluorescence intensity units for microarray and FPKM for RNA-Seq. Thus, the primary analysis in each phenotypic group was conducted with the untransformed readouts from each platform. The R/NR analysis was conducted by comparing the subtracted (LOCF--baseline) values in Rs to NRs. Fold changes for RT-qPCR and microarray data were determined by averaging the 2\^subtracted values (2^-ddCt^ for RT-qPCR) from each patient. For RNA-Seq FPKM, which is not an exponentiated value as for RT-qPCR and microarray data, the within R (or SR) and NR groups average fold change was determined by subtracting log2 transformed baseline values from the LOCF values for each patient, and then converting the difference to the base 2 antilog, i.e. 2\^((Log2 LOCF FPKM)---(Log2 baseline FPKM)) and averaging for all members of the group. Fold change for R/NR was calculated by dividing the R by the NR fold change.

### Statistical tests {#sec015}

Baseline to LOCF changes in mRNA abundance within Responder (R) and Nonresponder (NR) groups were assessed by the Wilcoxon signed-rank test. Between group changes (R/NR analysis) were determined by Wilcoxon rank sum test. LVEF and RVEF were analyzed by t-tests, as the data were not significantly non-normally distributed by the Anderson-Darling test. Potential differences in categorical variables were assessed by Chi-Square or Fisher's exact test for small cell sizes, with a Benjamini-Hochberg \[[@pone.0221519.ref020]\] adjustment for multiplicity. Alpha was set at 0.05 (2-sided P \<0.05) for selection of differentially expressed genes (DEGs) on changes from baseline within R or NR groups, and in R/NR analyses. Rank correlation analysis was performed using Spearman's Rho. Statistical analyses were performed on the R statistical package \[[@pone.0221519.ref021]\].

### Cross-platform or cross-cohort concordance {#sec016}

Concordant change was defined as the same directional change at a P \<0.05 in each compared platform. *Total Cross-Platform Concordance* (C~cpT~) in % for mRNA abundance changes (up plus down-regulated genes, "DEGs") between platforms within the same cohort (*A-S* or *S-R*) and response (NR, R or R/NR) was calculated from the formula \[[@pone.0221519.ref022]\] $$C_{cpT} = 100 \cdot \frac{2 \cdot {intersect}\left( {{DEGs}_{{Platform}\ 1},{DEGs}_{{Platform}\ 2}} \right)}{{DEGs}_{{Platform}\ 1} + {DEGs}_{{Platform}\ 2}}$$ where *intersect* is the number of genes with concordant changes.

When applied to 2 platforms measuring an identical set of genes' mRNA expression this formula is identical to that of Shi et al \[[@pone.0221519.ref023]\], used to derive "POG", or percentage of overlapping genes, from 2 lists of platform specific gene expression changes. The same formula can be used to derive cross-cohort performance (C~ccT~) in the same platform.

### Gene categorization and network analyses {#sec017}

Genes exhibiting concordant changes were categorized by a subgroup of the authors (JAS, EMR, MRB) based on manual curation of literature and NCBI website information relevant to myocardium. Canonical pathways, biological functions and gene networks were generated through Ingenuity Pathway Analysis (IPA) \[[@pone.0221519.ref024]\] (<https://www.qiagenbioinformatics.com/products/ingenuity-pathway-analysis>). "Superheat" maps were generated by the Barter-Yu graphical tool using R \[[@pone.0221519.ref025]\]. Column and row ordering of heatmaps was determined by hierarchical cluster solution for LVEF change tertile 3 subjects.

### Source data and protocol warehousing {#sec018}

Source data files from the 3 measurement platforms plus clinical data are warehoused in the GitHub repository (<https://bristowlab.github.io/borg.html>). Endomyocardial biopsy, RNA extraction and mRNA measurement protocols are available at <https://www.protocols.io/view/borg-protocols-2uggetw/abstract>.

Results {#sec019}
=======

Cross-platform concordance {#sec020}
--------------------------

### Candidate genes in the *A-S* cohort {#sec021}

[Responder (R) group analysis.]{.ul} For the 50 candidate genes, in the *A-S* cohort we compared mRNA measurements determined by microarray and RT-qPCR ([Table 1](#pone.0221519.t001){ref-type="table"}). In the change from baseline Responder analysis, 23 (46%) of the 50 candidate gene module exhibited changes by RT-qPCR, and 24 (48%) by microarray. For downregulated genes, in RT-qPCR there were 18 changes (P = 0.0009 vs. upregulated) and 14 in microarray. The C~cpT~ for all concordant changes in both platforms was 60% ([Table 1](#pone.0221519.t001){ref-type="table"}). In the R analysis 33 (66%) of the 50 candidate genes exhibited changes by either RT-qPCR or microarray.

10.1371/journal.pone.0221519.t001

###### Comparison of significantly different (P \<0.05) candidate genes (of 50 total mRNAs measured) detected by RT-qPCR or microarray in the *A-S* cohort.

![](pone.0221519.t001){#pone.0221519.t001g}

  Directional Change                                                                                        RT-qPCR Genes   Microarray Genes   Concordant Genes                                                      
  --------------------------------------------------------------------------------------------------------- --------------- ------------------ ------------------ -------- ------- ------- -------- -------- ------- -------
  Upregulated                                                                                               ADRB1           2.13               ADRB1              1.64     ADRB1   1.33    ADRB2    1.17     ADRB1   ADRB2
  PDK4                                                                                                      1.02            ADRB2              1.35               ADRB2    1.24    PFKM    1.08     PLN      PFKM    
  PLN                                                                                                       1.41            ADRA1A             1.55               HNRNPD   1.06    PLN     1.11     THRA1    PLN     
  TNNT2                                                                                                     1.07            PFKM               1.37               ADRA1A   1.21    RYR2    1.10              RYR2    
  THRA1                                                                                                     1.50            PDHX               1.19               AGTR1    1.48    MYH6    1.35              MYH6    
                                                                                                                            CPT1B              1.56               PFKM     1.05    MYL3    1.05              MYL3    
                                                                                                                            ATP2A2             1.70               PLN      1.12                                      
                                                                                                                            PLN                1.53               RYR2     1.10                                      
                                                                                                                            RYR2               1.33               MYL3     1.03                                      
                                                                                                                            MYH6               3.31               THRA1    1.10                                      
                                                                                                                            MYL3               2.01                                                                  
  N                                                                                                         5                                  11                          10              6                 3       6
  Downregulated                                                                                             GNAS            0.94               NPPA               0.61     GNAI2   0.94    SLC9A1   0.90     GNAI2   NPPA
  GNAI2                                                                                                     0.77            NPPB               0.65               SLC9A1   0.88    EDN1    0.79     SLC9A1   NPPB    
  SLC9A1                                                                                                    0.63                                                  EDN1     0.87    ACTA1   0.87     HK2              
  HK2                                                                                                       0.58                                                  HK2      0.86    TNNI3   0.96     CASQ2            
  PDHX                                                                                                      0.74                                                  CASQ2    0.93    DMD     0.93     SLC8A1           
  CASQ2                                                                                                     0.87                                                  SLC8A1   0.91    NPPA    0.71     ACTA1            
  SLC8A1                                                                                                    0.67                                                  CANX     0.96    NPPB    0.40     TNNI3            
  ACTA1                                                                                                     0.81                                                  ACTA1    0.87                     NPPA             
  ACTC1                                                                                                     0.83                                                  TNNI3    0.96                     NPPB             
  MYL2                                                                                                      0.83                                                  DMD      0.91                     CSRP3            
  TNNC1                                                                                                     0.98                                                  NPPA     0.74                     IL6              
  TNNI3                                                                                                     0.96                                                  NPPB     0.52                                      
  NPPA                                                                                                      0.71                                                  CSRP3    0.98                                      
  NPPB                                                                                                      0.66                                                  IL6      0.90                                      
  CSRP3                                                                                                     0.76                                                                                                     
  CTF1                                                                                                      0.85                                                                                                     
  IL6                                                                                                       0.91                                                                                                     
  THRA2                                                                                                     0.82                                                                                                     
  N                                                                                                         18              \-                 2                  \-       14      \-      7        \-       11      2
  **Overall Total number and % Concordance (C**~**cpT**~**), both platforms, up and downregulated genes**   28/47           16/26                                                                                    
  (60%)                                                                                                     (62%)                                                                                                    

[R/NR analysis.]{.ul} For the R/NR analysis ([Table 1](#pone.0221519.t001){ref-type="table"}) 18 (36%) of the 50 candidate genes exhibited changes by either RT-qPCR or microarray (vs. R, P = 0.059 for RT-qPCR, 0.023 for microarray, and 0.003 for both platforms). For upregulated genes RT-qPCR identified 11 and microarray 6 changes, all of which were concordant with RT-qPCR. For downregulated genes, RT-qPCR identified 2 (P = 0.007 vs. upregulated) changes that were both concordant with microarray measurements, which had 7 changes. The R/NR C~cpT~ was 62%.

### Candidate gene expression measured by three platforms in the *S-R* cohort {#sec022}

In the *S-R* cohort all three platforms generated measurements, shown in [Table 2](#pone.0221519.t002){ref-type="table"}. Only one change was concordant in all 3 platforms, marked downregulation (by \>90%) in the natriuretic peptide NPPB, a biomarker of ventricular myocardial hypertrophy, in the R/NR analysis. The Na^+^/H^+^ antiporter SLC9A1 (NHE1), which is involved in mediation of β~1~-adrenergic signaling of hypertrophy \[[@pone.0221519.ref026]\], exhibited two platform concordance between RNA-Seq and RT-qPCR for R, and RNA-Seq and microarray for R/NR.

10.1371/journal.pone.0221519.t002

###### Candidate genes in *S-R* cohort, mRNA expression fold changes from baseline within NR, R groups or comparison of R, NR fold changes (R/NR), changes with P \<0.05.

![](pone.0221519.t002){#pone.0221519.t002g}

  Directional Change                                 Gene                  RT-qPCR        Microarray   RNA-Seq                                   
  -------------------------------------------------- --------------------- -------------- ------------ -------------- ----------- -------------- ------
  Upregulated                                        ADRB1                 **1.86**                                               **1.60**       1.47
  AGTR1                                              **1.66**                                                         **1.81**                   
  PLN                                                1.32                                                                                        
  ATP2A2                                                                   **1.41**                                   1.39        **1.38**       
  MYH6                                                                                                                            2.74           
  MYL3                                                                                                 **1.07**       1.51        **1.50**       
  GNAQ                                                                                                 1.11                                      
  PFKM                                                                                                 1.10                                      
  RYR2                                                                                                 1.18                                      
  ADCY5                                                                                                               1.20                       
  CPT1B                                                                                                               1.18                       
  IL6ST                                                                                                                                          
  THRA                                                                                                                                           
  ADRB2                                                                                                                                          
  NPPB                                                                                                                                           
  Totals                                             15^‡^                 3              1            0              5           6              4
  Upregulated                                        AGT                   0.83                                                                  
  CASQ2                                              0.62                  **0.57**                                               **0.73**       
  DMD                                                0.81                                                                                        
  GNAI2                                              0.73                                                                                        
  HK2                                                0.31                                                                                        
  IL6                                                0.44                                                                                        
  NPPB                                               **0.05**              ***0*.*07***                ***0*.*07***   **0.078**   ***0*.*06***   
  PDHX                                               0.75                                                                                        
  SLC8A1                                             0.63                                                                                        
  SLC9A1                                             **0.46**                                          **0.77**       **0.64**    **0.56**       
  MYL2                                                                                                                            0.62           
  TNNI3                                                                                                0.94                                      
  PDHX                                                                                                                0.84                       
  ADRBK1                                                                                  0.93                                                   
  GNAQ                                                                                                                                           
  PLN                                                                                                                                            
  RYR2                                                                                                                                           
  Totals                                             17                    10             2            1              3           3              4
  Total up- or downregulated genes                   13                    3              1            8              9           8              
  16                                                 9                     17                                                                    
  P value for up, down-regulated genes in R + R/NR   0.15                                                                                        
  C~cpT~, ≥2 platforms^‡^                            4/13)                 3/3            0/1          3/8            4/9         5/8            
  (31%)                                              (100%)                (0%)           (38%)        (44%)          (62%)                      
  Cross-platform C~cpT~ P values                     R, 0.02; R/NR, 0.18                                                                         

Cross-platform concordant (C~cpT~) fold change in 2 platforms is in **bold type**, in 3 platforms in ***bold type*, *italics)*.**

\*Wilcoxon sign rank test for change from baseline

^†^Wilcoxon rank sum test comparing changes in NR to R^‡^≥platforms = concordance in comparison of any 2 platforms (doesn't require 3 platform concordance).

The relatively small, N = 12 *S-R* cohort provided an opportunity to assess sensitivity of change detection among the 3 platforms. Of the 50 candidate genes, RT-qPCR, microarray and RNA-Seq yielded respectively 16, 9 and 17 statistically significant changes from baseline (R + R/NR analyses), P = 0.15 for change detection among platforms. The C~cpT~ value within specific platforms calculated as agreement with at least 1 other platform trended lower in microarray vs. respective values in RT-qPCR or RNA-Seq (in R 0% vs. 31% and 44%, P = 0.02; in R/NR 38% vs. 100% and 62%, P = 0.18).

### Global gene expression in the *S-R* cohort, measured by microarray and RNA-Seq {#sec023}

Microarray and RNA-Seq platform measurements of global gene expression were used to investigate change concordance in the *S-R* cohort. Microarray detected 19,672 individual gene transcripts and 15,364 (78%) of these were also detected by RNA-Seq, forming the index number of measurements for analysis. [S2 Table](#pone.0221519.s004){ref-type="supplementary-material"} gives the alpha 0.05 list of up- or down-regulated genes within R and R/NR analyses, which are summarized in the denominators for change and concordance calculations at the bottom of [Table 3](#pone.0221519.t003){ref-type="table"}.

10.1371/journal.pone.0221519.t003

###### Cross-platform concordance of global gene expression changes, mRNA measurements by array and RNA-Seq in the *S-R* cohort, responder and R/NR datasets, changes at alpha 0.05.

![](pone.0221519.t003){#pone.0221519.t003g}

  Upregulated                                                             Downregulated                                                                                                                                                                                                                                
  ----------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------ -------------------------------------- ------------------------------------------- ----------- ---------- ---------- ---------- ---------
  BPHL                                                                    ADAM11                                                                                                       MYLK4                                  CXCL5                                       AATF        CYP19A1    MAP7       RRAS       ZMYND17
  DHFRL1                                                                  ADCYAP1R1                                                                                                    NCR00201                               EGLN3                                       ABAT        DCBLD2     MEG3       RSPH3      ZNRF2
  FEZ1                                                                    ALDH2                                                                                                        NDUFB9                                 EIF2C1                                      ABCD1       DDA1       MELK       SDSL       42989
  KANK1                                                                   AMD1                                                                                                         PDE7B                                  FUCA2                                       ABHD12      DHCR24     MEST       SERPINE2   42797
  LDB2                                                                    AQP7                                                                                                         PEBP4                                  KCTD9                                       ACAD11      DLK2       MFI2       SETD3      42982
  NUDT4                                                                   ART3                                                                                                         PHACTR3                                KP1                                         ACE2        DOK4       MLLT11     SGK1       
  PHACTR3                                                                 ASB10                                                                                                        PIM3                                   LUZP1                                       ACTN1       DSYN1      MOXD1      SGTA       
  PKD1L1                                                                  ATP5I                                                                                                        PLA2G4F                                PRKCA                                       ADC         E2F1       MPV17      SH2D4A     
  PRELID2                                                                 BCL11A                                                                                                       PLAG1                                  RHBDD1                                      ALDH3A2     EIF4G3     MPV17L2    SH3GL2     
  RG9MTD3                                                                 BCL6                                                                                                         PLCL2                                  TSPAN17                                     APLP1       ENC1       MTMR3      SH3GLB1    
  SEC16B                                                                  C1orf105                                                                                                     POLR2I                                 USP9Y                                       APOA1       ENO3       MXRA5      SHB        
  SLC26A9                                                                 C3orf43                                                                                                      PPP1R1A                                VTI1B                                       APOL4       ENOX2      MYOZ3      SHC2       
  SYCP3                                                                   C7orf70                                                                                                      PRELID2                                                                            ARHGAP11A   EXOC6B     NCAPH      SHROOM3    
  TPSAB1                                                                  CACYBP                                                                                                       RAF1                                                                               ARSD        EXT1       NEB        SIRPA      
  ZNF135                                                                  CD5L                                                                                                         RET                                                                                ARSE        EXTL3      NOTCH2NL   SLC1A4     
                                                                          CEL                                                                                                          RNF165                                                                             ASPM        FARP1      NPPB       SLC1A7     
                                                                          CHDH                                                                                                         RORC                                                                               ATP6V1E2    FN1        NPR3       SLC9A1     
                                                                          CKM                                                                                                          RPL24                                                                              ATRNL1      FOXM1      ODC1       SMAD6      
                                                                          COL28A1                                                                                                      SCN1A                                                                              BEX1        GDF11      OGDHL      SMOC2      
                                                                          COLEC12                                                                                                      SCN7A                                                                              BGN         GRN        ORMDL3     SNCA       
                                                                          CORIN                                                                                                        SDK1                                                                               C11orf24    HCCS       P1L4       SOCS2      
                                                                          CPA3                                                                                                         SEPP1                                                                              C1orf21     HELB       PACSIN1    SPINT2     
                                                                          DLK1                                                                                                         SHISA3                                                                             C5orf46     HERC5      PAPPA2     SPTAN1     
                                                                          DH11                                                                                                         SLC19A2                                                                            C7orf53     HEXB       PCSK5      SRPX2      
                                                                          FAM124A                                                                                                      SLC26A9                                                                            C9orf30     HLX        PDE1A      ST3GAL4    
                                                                          FAM179A                                                                                                      SLC27A6                                                                            CALU        HMGB3      PDE8B      STK17A     
                                                                          FGFBP2                                                                                                       SYCP3                                                                              CASQ1       HTRA1      PDLIM4     SVEP1      
                                                                          FNDC5                                                                                                        SYT3                                                                               CC2         INPP4B     PDPN       SVIL       
                                                                          GALNTL1                                                                                                      THAP1                                                                              CCNJL       IQGAP3     PENK       SYTL4      
                                                                          GRIN2A                                                                                                       TJP2                                                                               CDC25A      JAZF1      PGBD5      SYTL5      
                                                                          GZMK                                                                                                         TKTL1                                                                              CDH17       KCB1       PHYHIP     TBC1D22A   
                                                                          HADHB                                                                                                        TMEM132C                                                                           CDH2        KCNC4      PI16       TFDP2      
                                                                          HEY2                                                                                                         TPRKB                                                                              CDK8        KCNJ4      PIK3R2     TGOLN2     
                                                                          HIST3H2A                                                                                                     TPSAB1                                                                             CENPA       KCNJ5      PLCD4      THBS4      
                                                                          HMGCS2                                                                                                       UCKL1                                                                              CENPN       KIAA0556   PLCE1      TMED3      
                                                                          HSPB3                                                                                                        VRK2                                                                               CHD3        KIAA1244   PLIN3      TMEM51     
                                                                          IL6R                                                                                                         VWA3A                                                                              CHMP4B      KIAA1539   POLR1E     TNNT1      
                                                                          KAT2B                                                                                                        WDSUB1                                                                             CHMP4C      KIF4A      PORCN      TOP2A      
                                                                          KCNJ2                                                                                                        WNT5A                                                                              CHPF2       KLHL6      PROS1      TPD52L1    
                                                                          KIAA1328                                                                                                     ZBED5                                                                              CKAP4       LGALS9     PTPRH      TPM3       
                                                                          LARP4B                                                                                                       ZNF33B                                                                             CLTCL1      LGI2       QPCT       TPX2       
                                                                          LPAR3                                                                                                        ZNF585A                                                                            COL18A1     LNP1       QSOX1      TRIM41     
                                                                          LRRC39                                                                                                                                                                                          COL1A1      LOXL1      RAB15      TSPAN5     
                                                                          MCF2                                                                                                                                                                                            COL23A1     LOXL2      RAB31      TSTA3      
                                                                          MLPH                                                                                                                                                                                            COL4A1      LTBP2      RAB6B      UBR1       
                                                                          MRO                                                                                                                                                                                             CRELD1      LUZP1      RASL11B    UNC13C     
                                                                          MRPL43                                                                                                                                                                                          CRLF1       LYPD1      RCAN1      VDR        
                                                                          MRPS24                                                                                                                                                                                          CTGF        MAGED2     RELL1      WDR77      
                                                                          MTSS1                                                                                                                                                                                           CUX1        MAP1A      RGS4       WHSC1      
                                                                          MYL3                                                                                                                                                                                            CYP11A1     MAP2       RNF214     XPO4       
  **(N)/total changes, Array or RNA-Seq**                                                                                                                                                                                                                                                                              
  15/279 (Array)                                                          92/869 (Array)                                                                                               12/294 (Array)                         205/936 (Array)                                                                          
  15/631 (RNA-Seq                                                         92/378 (RNA-Seq)                                                                                             12/1093 (RNA-Seq)                      205/1078 (RNA-Seq)                                                                       
                                                                          **Total Cross-Platform Concordance (C**~**cpT**~**), both platforms, upregulated and downregulated genes**                                                                                                                                   
  −                                                                       −                                                                                                            **R: 54/2297 (C**~**cpT**~ **2.4%)**   **R/NR: 594/3401 (C**~**cpT**~ **17.5%)**                                                
  **(27 genes with changed expression in both microarray and RNA-Seq)**   **(297 genes with changed expression in both microarray and RNA-Seq)**                                                                                                                                                                       

[R analysis.]{.ul} In the R analysis microarray detected 573 genes with mRNA changes, or 2.9% of the transcripts measured (279 upregulated and 294 downregulated, P = 0.53). RNA-Seq identified 1724 changes (11.2% of the transcripts measured, P \<0.0001 vs. microarray), consisting of 631 upregulated and 1093 downregulated genes (P \<0.0001). Concordance analysis between microarray and RNA-Seq ([Table 3](#pone.0221519.t003){ref-type="table"}) yielded a total of 27 genes in the R analysis (15 upregulated and 12 downregulated), for a C~cpT~ for any gene expression change of 2.4%.

[R/NR analysis.]{.ul} In the R/NR analysis microarray identified 1805 genes with changed expression (9.2% of total mRNAs measured, 869 upregulated and 936 downregulated, P = 0.11), while RNA-Seq detected 1456 changes (9.5% of total measured transcripts), of which 378 were upregulated and 1078 downregulated (P \<0.0001). The R/NR dataset exhibited 297 changes that were concordant between microarray and RNA-Seq (92 upregulated and 205 downregulated (P \<0.0001)) ([Table 3](#pone.0221519.t003){ref-type="table"}), with a combined platform C~cpT~ of 17.5% (P \<0.0001 vs. *A-S* R/NR (PCR/microarray) C~cpT~ of 62%). The within *S-R* C~cpT~ comparison between candidate (6/16, 38%) and global changes measured by microarray/RNA-Seq yielded a P value of 0.036. [Table 4](#pone.0221519.t004){ref-type="table"} contains a biologic categorization of genes with concordantly changed expression for the microarray/RNA-Seq R/NR analysis in the *S-R* cohort, with the category assignments for each gene given in [S3 Table](#pone.0221519.s005){ref-type="supplementary-material"}. For all 297 genes with cross-platform concordantly changed expression, the disproportionate downregulation by a factor of 2.2 fold compared to upregulation is due to changes in the Growth/Hypertrophy (P = 0.026, Hochberg adjusted P = 0.078), Cell Homeostasis (respective Ps 0.005, 0.027), Fibroblast Growth/extracellular matrix (Ps 0.001, 0.008), Extracellular to Intracellular Signaling (Ps 0.022, 0.077), Cytoskeleton (Ps 0.041, 0.10), and Unclassified/unknown Function (Ps = 0.002, 0.016) categories. [S3 Table](#pone.0221519.s005){ref-type="supplementary-material"} is a more detailed biologic categorization of genes with concordant expression changes in *S-R*, to which 2 additional candidate genes that were concordantly changed by RT-qPCR and RNA-Seq (upregulation in ATP2A2 and downregulation in CASQ2, [Table 2](#pone.0221519.t002){ref-type="table"}) have been added.

10.1371/journal.pone.0221519.t004

###### Biologic categories of concordant global gene expression changes measured by microarray and RNA-Seq in the *S-R* cohort, R/NR analysis (from [Table 3](#pone.0221519.t003){ref-type="table"}).

![](pone.0221519.t004){#pone.0221519.t004g}

  Biologic Category                                                                                                                Up-regulated   Down-regulated   P value[\*](#t004fn001){ref-type="table-fn"}   P-value, Adjusted[^†^](#t004fn002){ref-type="table-fn"}
  -------------------------------------------------------------------------------------------------------------------------------- -------------- ---------------- ---------------------------------------------- ---------------------------------------------------------
  Contractile and associated proteins                                                                                              3              2                1.00                                           1.00
  Metabolism                                                                                                                       8              9                1.00                                           1.00
  Growth/hypertrophy Regulation                                                                                                    8              21               0.026                                          0.078
  Channels, Solute Exchangers, Transporters                                                                                        8              7                1.00                                           1.00
  Ca2+ Handling or signaling                                                                                                       0              1                1.00                                           1.00
  Cell Homeostasis (Golgi, ER, membrane and cytosol trafficking)                                                                   8              25               0.005                                          0.027
  Fibroblast growth, Extracellular Matrix or TGF signaling                                                                         3              21               0.001                                          0.008
  Extracellular to intracellular signaling[^‡^](#t004fn003){ref-type="table-fn"}                                                   16             33               0.022                                          0.077
  Apoptosis                                                                                                                        2              8                0.11                                           0.24
  Microtubules                                                                                                                     0              3                0.25                                           0.41
  Immune function other than cytokines                                                                                             5              2                0.45                                           0.68
  Vascular/thrombosis                                                                                                              1              3                0.62                                           0.84
  Cytoskeleton                                                                                                                     0              6                0.041                                          0.10
  Gene regulation: Transcription factors, RNA binding, nucleotide processing, translation, nucleosome components, noncoding RNAs   14             24               0.14                                           0.27
  Unclassified/Unknown Function In the heart                                                                                       16             40               0.002                                          0.016
  **Totals**                                                                                                                       92             205              P \<0.0001                                     

\*Chi-square Test for differences in proportions.

†P-value adjustment via Benjamini-Hochberg.

‡Includes neurohormonal signaling, PI3K, PLC, Small GTPases and regulators, cytokines, and other signaling pathways.

RNA-Seq detected more genes with changed expression in R than in R/NR (1724 vs. 1456, p \<0.0001), while microarray identified more changes in R/NR than R (1805 vs. 573, p \<0.0001). C~cpT~ was 6.2 fold higher in R/NR compared to R ([Table 3](#pone.0221519.t003){ref-type="table"}). The C~cpT~ of 2.4% in R for global gene expression was matched by a 0% (no concordance in 10 changes) for microarray/RNA-Seq in *S-R* ([Table 2](#pone.0221519.t002){ref-type="table"}). For R/NR C~cpT~ was higher, 17.5% for global ([Table 3](#pone.0221519.t003){ref-type="table"}, P \<0.0001 vs. R) and 38% (6/16) for candidate gene microarray/RNA-Seq ([Table 2](#pone.0221519.t002){ref-type="table"}, P = 0.053 vs. R, 0.036 vs. global R/NR).

Cross-cohort comparisons {#sec024}
------------------------

In order to derive direct information on whether smaller cohorts of hyper-responders can substitute for larger cohorts comprised of smaller degrees of phenotypic response in longitudinal reverse remodeling gene expression studies, we compared measurements between the *A-S* and *S-R* cohorts using data from RT-qPCR for candidate genes and microarray for global gene expression.

### Cross-cohort concordance for candidate gene expression changes in *A-S* vs. *S-R* assessed by RT-qPCR {#sec025}

[R analysis.]{.ul} Genes with p \<0.05 changes in expression for RT-qPCR measurements, the protocol primary method for candidate gene mRNA change detection \[[@pone.0221519.ref008]\], are given for the 2 cohorts in [Table 5](#pone.0221519.t005){ref-type="table"}. In the *A-S* cohort R analysis, 23 genes exhibited expression changes (5 upregulated and 18 downregulated, P = 0.002), while 13 changes were identified in the *S-R* cohort (3 upregulated, 10 downregulated, P = 0.037) (P = 0.059 vs. total changes in *A-S*). Thus, in the R analysis RT-qPCR identified more down-regulated genes in both the *A-S* and S-R cohorts. The two cohorts were concordant for 2 upregulated (ADRB1 and PLN) and 8 downregulated (GNAI2, SLC9A1, AGT, HK2, PDHX, CASQ2, SLC8A1, DMD, NPPB and IL6*)* genes ([Table 5](#pone.0221519.t005){ref-type="table"}, P = 0.046). Within the R group the 10 concordantly changed genes in the *A-S* and *S-R* cohorts were from a total of 35 upregulated and downregulated genes, for a C~ccT~ of 56% ([Table 5](#pone.0221519.t005){ref-type="table"}).

10.1371/journal.pone.0221519.t005

###### Cross-cohort candidate gene concordance of RT-qPCR in the *A-S* vs. *S-R* cohorts (changes of P \< 0.05).

![](pone.0221519.t005){#pone.0221519.t005g}

  Directional Change   RT-qPCR *S-R* Genes                                                            RT-qPCR *A-S* Genes   Concordant Genes                                                      
  -------------------- ------------------------------------------------------------------------------ --------------------- ------------------ -------- ------- -------- ------- -------- ------- --------
  Upregulated          ADRB1                                                                          1.86                  ATP2A2             1.72     ADRB1   2.13     ADRB1   1.64     ADRB1   ATP2A2
  AGTR1                1.66                                                                                                                    PDK4     1.02    ADRB2    1.35    PLN              
  PLN                  1.32                                                                                                                    PLN      1.41    ADRA1A   1.55                     
                                                                                                                                               TNNT2    1.07    PFKM     1.37                     
                                                                                                                                               THRA1            PDHX     1.19                     
                                                                                                                                                                CPT1B    1.56                     
                                                                                                                                                                ATP2A2   1.70                     
                                                                                                                                                                PLN      1.53                     
                                                                                                                                                                RYR2     1.33                     
                                                                                                                                                                MYH6     3.31                     
                                                                                                                                                                MYL3     2.01                     
  N                    3                                                                                                    1                           5                11               2       1
  Downregulated        GNAI2                                                                          0.73                  CASQ2              0.57     GNAS    0.94     NPPA    0.61     GNAI2   NPPB
  SLC9A1               0.46                                                                           NPPB                  0.07               GNAI2    0.77    NPPB     0.65    SLC9A1           
  AGT                  0.83                                                                                                                    SLC9A1   0.63                     HK2              
  HK2                  0.31                                                                                                                    HK2      0.58                     PDHX             
  PDHX                 0.75                                                                                                                    PDHX     0.74                     CASQ2            
  CASQ2                0.62                                                                                                                    CASQ2    0.87                     SLC8A1           
  SLC8A1               0.63                                                                                                                    SLC8A1   0.67                     NPPB             
  DMD                  0.81                                                                                                                    ACTA1    0.81                     IL6              
  NPPB                 0.05                                                                                                                    ACTC1    0.83                                      
  IL6                  0.44                                                                                                                    MYL2     0.83                                      
                                                                                                                                               TNNC1    0.98                                      
                                                                                                                                               TNNI3    0.96                                      
                                                                                                                                               NPPA     0.71                                      
                                                                                                                                               NPPB     0.66                                      
                                                                                                                                               CSRP3    0.76                                      
                                                                                                                                               CTF1     0.85                                      
                                                                                                                                               IL6      0.91                                      
                                                                                                                                               THRA     0.82                                      
  N                    10                                                                             \-                    2                  \-       18      \-       2       \-       8       1
                       **Total Cross-Cohort Concordance (C**~**ccT**~**), up, downregulated genes**   **20/36**             **4/16**                                                              
  **56%**              **25%**                                                                                                                                                                    

[R/NR analysis]{.ul}. Within the R/NR dataset of the *A-S* cohort 11 genes were upregulated while 2 genes were downregulated ([Table 5](#pone.0221519.t005){ref-type="table"}, P = 0.007) ([Table 5](#pone.0221519.t005){ref-type="table"}). In the *S-R* cohort 1 gene was upregulated while 2 were downregulated (total changes of 3 vs. 13 in *A-S*, P = 0.006). The 2 cohorts were concordant for 1 upregulated (ATP2A2) and 1 downregulated gene (NPPB), for a C~ccT~ of 25% ([Table 5](#pone.0221519.t005){ref-type="table"}; P = 0.033 vs. R Group analysis).

[Cross-platform comparisons between *S-R* and *A-S* cohorts]{.ul}. For candidate genes cross-platform concordance was compared between the *S-R* and *A-S* cohorts, using the 2 platform PCR/microarray comparison. Compared to the *A-S* cohort ([Table 1](#pone.0221519.t001){ref-type="table"}), for the R analysis PCR/microarray C~cpT~ in *S-R* ([Table 2](#pone.0221519.t002){ref-type="table"}) was 0/14 = 0% (P = 0.01 vs. C~cpT~ of 60% in *A-S*), and 2/11 = 18% for R/NR (P = 0.016 vs. C~cpT~ of 62% in *A-S*). Compared to PCR/microarray the *S-R* PCR/RNA-Seq C~cpT~ values were higher, 8/22 (36%) (P = 0.03 vs. *S-R* PCR/microarray) in R and 6/11 (55%, P = 0.08) in R/NR ([Table 2](#pone.0221519.t002){ref-type="table"}). The *S-R* R and R/NR C~cpT~ values for microarray/RNA-Seq were respectively 0/10 (P = 0.07 vs. PCR/RNA-Seq) and 6/16 = 38% (P = 0.38 vs. PCR/RNA-Seq) ([Table 2](#pone.0221519.t002){ref-type="table"}). Thus, candidate gene cross-platform concordance for PCR/microarray was not as good in *S-R* as compared to the *A-S* cohort, but the higher 2 platform concordances of PCR/RNA-Seq vs. microarray containing C~cpT~ combinations suggests part of the issue was microarray platform related.

### Cross-cohort concordance for global gene expression changes as assessed by microarray {#sec026}

[R Analysis.]{.ul} The number of significantly different global genes based on microarray measurements in the *S-R* cohort is given in [S2 Table](#pone.0221519.s004){ref-type="supplementary-material"}, and for the *A-S* cohort in [S4 Table](#pone.0221519.s006){ref-type="supplementary-material"}. The R group analysis yielded a total of 2931 upregulated genes in the *A-S* cohort (represented in the denominator of total changes in [S5 Table](#pone.0221519.s007){ref-type="supplementary-material"}, while 2294 upregulated genes were detected in the *S-R* cohort (p \<0.0001). A total of 3274 downregulated genes were identified in the *A-S* cohort while 2095 genes were detected in the *S-R* cohort (p \<0.0001). There were only 60 upregulated and 42 downregulated concordant changes, for a C~ccT~ of 1.9% ([S5 Table](#pone.0221519.s007){ref-type="supplementary-material"}).

[R/NR analysis.]{.ul} In the R/NR patient group microarray detected 850 upregulated genes in the *A-S* cohort ([S4 Table](#pone.0221519.s006){ref-type="supplementary-material"}), while 869 were detected in the *S-R* cohort ([S2 Table](#pone.0221519.s004){ref-type="supplementary-material"}). Downregulated genes were n = 1085 in the *A-S* cohort ([S4 Table](#pone.0221519.s006){ref-type="supplementary-material"}), and 936 in the *S-R* cohort ([S2 Table](#pone.0221519.s004){ref-type="supplementary-material"}, P = 0.0006 vs. *A-S*). In marked contrast to the R analysis, the R/NR analysis had much higher concordance in both up- (N = 391) and down- (N = 393) regulated genes, with a C~ccT~ of 42% (P \<0.0001 vs. R analysis) ([S5 Table](#pone.0221519.s007){ref-type="supplementary-material"}).

Platform concordance of gene expression changes has biologic significance {#sec027}
-------------------------------------------------------------------------

The *A-S* cohort, which had LVEF changes ranging from -8 to 47.5 absolute %, created the opportunity to examine the relationship between reverse remodeling as a biologic effect and cross-platform concordance of gene expression changes. For changes from baseline, candidate gene microarray and RT-qPCR C~cpT~ values were related to LVEF change tertiles ([Fig 2](#pone.0221519.g002){ref-type="fig"}, [S6 Table](#pone.0221519.s008){ref-type="supplementary-material"}). The first tile of LVEF change ([Fig 2](#pone.0221519.g002){ref-type="fig"}) corresponds to the NR group (LVEF change in absolute %±SD = 0.9±4.4%), while the 2^nd^ and 3^rd^ tiles consist of R group subjects that have respective LVEF increases of 13.3±4.0 and 29.6±6.1 absolute %. There were no differences in baseline LVEF values, which ranged from 27.8% in tile 1 to 23.6% in tile 3 (ANOVA P = 0.32). The tiles 2 and 3 LOCF LVEFs were respectively 40.9% and 53.1% ([Fig 2](#pone.0221519.g002){ref-type="fig"}), indicating phenotypic improvements into the HFmrEF (HF with "mid-range" LVEF) and normal ranges. The tile 1 LVEF remained in the lower range of HFrEF (P \<0.0001 across the 3 LOCF tiles).

![LVEF change and C~cpT~ by tertile.\
**(A)** LVEF change by tertile, mean ± SD in absolute %; (**B**) Gene expression change from baseline at P \<0.05, Overall Cross-platform Total % Concordance (C~cpT~) by tile. LVEF baseline → LOCF\* values (mean in % ± SD): Tile 1, 27.8±10.3 → 28.7±10.3; Tile 2, 27.6±8.4 → 40.9±10.5; Tile 3, 23.6±7.7 → 53.1±6.7. ANOVA P values: baseline = 0.32, LOCF \<0.0001.](pone.0221519.g002){#pone.0221519.g002}

By RT-qPCR there were respectively 25, 12 and 20 up or downregulation changes progressing up the tertile (P = 0.026) ([Fig 2](#pone.0221519.g002){ref-type="fig"}). Microarray measurements yielded 2, 13 and 17 respective changes (P = 0.008) by tertile. For both platforms the number of changed genes by tertile was 27, 25 and 37 (P = 0.033) progressing from Tiles 1 to 3, but tile 1 was not significantly different from tile 3 (P = 0.083) and there is no obvious reverse remodeling vs. gene expression change relationship, with tile 2 having numerically fewer changes than tiles 1 or 3. However, RT-qPCR and microarray cross-platform concordance exhibited a direct relationship to reverse remodeling across the LVEF tiles, with respective C~cpT~ values of 15%, 32% and 59% (overall P \< 0.001) ([Fig 2](#pone.0221519.g002){ref-type="fig"}, [S6 Table](#pone.0221519.s008){ref-type="supplementary-material"}). Thus, in a set of candidate genes enriched for having a possible relationship to LV remodeling, concordance of gene expression changes increases directly and substantially with the degree of reverse remodeling.

Gene network/signaling pathway analyses {#sec028}
---------------------------------------

### Pathway analyses of concordant R/NR changes {#sec029}

**Canonical pathways.** To investigate the possible canonical signaling pathways involved in the concordance related biological effect on LV remodeling, for microarray/RNA-seq concordant changes in global gene expression in *S-R* we conducted an Ingenuity Pathway Analysis (IPA) \[[@pone.0221519.ref024]\] on the 299 R/NR concordant genes listed in [S3 Table](#pone.0221519.s005){ref-type="supplementary-material"} with the results shown in [S7 Table](#pone.0221519.s009){ref-type="supplementary-material"}. The methodological background for the IPA analyses is given in the Supporting Information. [S3 Table](#pone.0221519.s005){ref-type="supplementary-material"} indicates there were 92 upregulated and 207 downregulated genes based on 297 concordantly changed genes in [Table 3](#pone.0221519.t003){ref-type="table"} and an additional 2 in [Table 2](#pone.0221519.t002){ref-type="table"}. Of the most negative z scores in [S7 Table](#pone.0221519.s009){ref-type="supplementary-material"} (values \< -1.5), evidence for a net pathway inhibition, 3 of them were phosphoinositide related pathways containing many of the same molecules (Superpathway of Inositol Phosphate compounds, 3-phosphonositide Degradation and D-myo-inositol-5-phosphate Metabolism), belonging to the biologic categories ([Table 4](#pone.0221519.t004){ref-type="table"}, [S3 Table](#pone.0221519.s005){ref-type="supplementary-material"}) of Growth/hypertrophy regulation (PTPRH, CDC25A), extracellular to intracellular signaling (PLCE1, PLCD4 (subcategory phospholipase C signaling), PPP1R1A (subcategory neurohormonal signaling); PIK3R2, INPP4B, MTMR3 (subcategory PI3 kinase signaling); and SIRPA (subcategory other signaling)). The other 2 pathways identified with z scores \< -1.5, GP6 Signaling and Dendritic Cell Maturation contained collagen and phospholipase C or PI3 kinase signaling molecules. GP6 is a collagen receptor expressed in platelets, but the IPA is likely detecting extracellular matrix collagen transcript downregulation.

Only 6 pathways had positive z scores (indicating net activation), with the highest, calcium signaling, considered statistically significant with a z-score of 2.00 and an overlapping P value of \< 0.01. Cardiac β-adrenergic signaling and protein kinase A signaling also had positive z-scores, in a clinical setting of high dose β~1~ adrenergic receptor blockade. Downstream of β~1~-adrenergic signal transduction is calcium signaling and the initiation and regulation of contractile function \[[@pone.0221519.ref027]\]. The 8 mRNA gene products grouped together within the calcium signaling Ingenuity canonical pathway in [S7 Table](#pone.0221519.s009){ref-type="supplementary-material"} are involved in calcium binding/uptake or release (GRIN2A, ATP2A2, CASQ1, CASQ2), or are directly or indirectly regulated or activated by calcium (RCAN1, MYL3, TPM3, TNNT1). In [S3 Table](#pone.0221519.s005){ref-type="supplementary-material"} they are members of the channels/solute exchanger/transporters (GRIN2A), Ca^2+^ handling or signaling (ATP2A2, CASQ1, CASQ2), contractile and associated proteins (MYL3, TPM3, TNNT1) or growth/hypertrophy regulation (RCAN1).

The second most positive z-score in the IPA was for Gα12/13 signaling ([S7 Table](#pone.0221519.s009){ref-type="supplementary-material"}), which has not been previously identified as having a molecular signature in the reverse remodeled failing human heart. GNA12 and GNA13 are closely related members of a class of pertussis-toxin insensitive G-proteins \[[@pone.0221519.ref028]\] that transduce signaling in lysophosphatidic acid (LPA), angiotensin II, endothelin-1, MAP kinase, PI3 kinase and other pathways involved in cardiac myocyte hypertrophy \[[@pone.0221519.ref028]--[@pone.0221519.ref031]\]. The Gα12/13 signaling module contained an upregulated LPA receptor (LPAR3), an upregulated MAP kinase kinase (RAF1), 2 downregulated cadherin genes (CDH2 and CDH17), a downregulated PI3 kinase regulatory subunit (PIK3R2) and an upregulated contractile protein gene, MYL3, the "essential" ventricular myosin light chain that is considered to be an "adult" expressed gene within the fetal-adult gene expression paradigm.

### Noncanonical disease associations {#sec030}

[Fig 3](#pone.0221519.g003){ref-type="fig"} is the "tox function" IPA analysis for 4 domains relevant to ventricular chamber remodeling. Failure (A), Dysfunction (B), Cell Death (C), and Fibrosis (D) of the heart are all predicted to be inhibited by the noncanonical gene expression changes in the *S-R* cohort (Tables [2](#pone.0221519.t002){ref-type="table"} and [3](#pone.0221519.t003){ref-type="table"}).

![Ingenuity pathway analysis of concordantly changed mRNAs from [Table 3](#pone.0221519.t003){ref-type="table"}.\
Colors indicate predicted effect of transcript on biological function or disease in center of circular diagram. (**A**) Dysfunction of heart. (**B**) Failure of heart. (**C**) Cell death of heart. (**D**) Dilated cardiomyopathy.](pone.0221519.g003){#pone.0221519.g003}

Correlation of candidate with global gene expression changes in *A-S* cohort {#sec031}
----------------------------------------------------------------------------

In the *A-S* cohort we used the "Superheat" \[[@pone.0221519.ref025]\] graphical package to assess the extent of microarray-measured candidate gene expression changes compared to those in the 19,672 global genes ([Fig 4](#pone.0221519.g004){ref-type="fig"}), within the LVEF change tertiles shown in [Fig 2](#pone.0221519.g002){ref-type="fig"}. In [Fig 4](#pone.0221519.g004){ref-type="fig"} the 19 genes that had concordant R or R/NR changes ([Table 1](#pone.0221519.t001){ref-type="table"}) are designated by arrows, and the 19,672 gene transcripts are displayed in individual horizontal rows that cannot be distinguished in the resolution. The heat map is arranged by degrees of correlated fold change ranging from a Rho of +1.0 (two genes, a candidate and a global) with log2 fold changes perfectly positively correlated to -1.0 (2 genes perfectly negatively correlated) in the 47 individual patients. The candidate genes along the x-axis are arranged by degree of correlation with the 19,672 global genes identified on microarray in tile 3 ([Fig 4C](#pone.0221519.g004){ref-type="fig"}); closer spatial proximity of candidate gene columns suggests similar patterns of correlation across non-candidate genes. In the 3^rd^ tile of LVEF change ([Fig 4C](#pone.0221519.g004){ref-type="fig"}, mean LVEF increase 29±6 absolute %) clear patterns of moderately positive or negative correlations are evident, which are not present in tiles 1 and 2 ([Fig 4A and 4B](#pone.0221519.g004){ref-type="fig"}; respective mean LVEF changes of 0.9±4 and 13±4 absolute %). In tile 3 ([Fig 4C](#pone.0221519.g004){ref-type="fig"}) there are 2 sets of candidate genes associated with reciprocal regulation of large numbers of global genes, which also contain a high percentage of concordant genes. Along the horizontal axis are candidate genes, ranging from GNAS to MYH7, which are positively (bottom part of the heat map) or negatively (middle-upper part) correlated of with large numbers of global genes' expression. Of the 19 candidate genes in this region, 7 are concordantly changed, with 6 being upregulated including both ADRB1 and ADRB2. The positive and negative portions of the map encompass approximately 28% and 30% of the 19,672 genes displayed. The 19 candidate genes in this "hot" region ("Group 1") have in common either being regulated by β~1~-AR signaling (n = 12; AGTR1, HNRNPD, MYL3, RYR2, ADRB2, PLN, ADRB2, PFKM, CTF1, ATP2A2, ADRA1A, MYH7), being involved in adrenergic receptor signal transduction (GNAS, GNAQ), being involved in Ca^2+^ handling or regulation (ATP2A2, SLC8A1, PLN, CANX), or being important in sarcomere structure (DMD, CTF1).

![Superheat maps.\
**(A)** Spearman's Rho of baseline vs. LOCF mRNA abundance, superheat map of 19,672 separate mRNA gene products (rows along Y-axis) vs. the 50 candidate gene mRNAs, patients in tile 1 of LVEF change ([Fig 2](#pone.0221519.g002){ref-type="fig"}). Arrows indicate candidate genes with concordant changes measured by RT-qPCR and microarray in either the R (Responder) or R/NR (Responder/Nonresponder) analysis; **(B)** Same as Fig 4A., except data are from tile 2 in [Fig 2](#pone.0221519.g002){ref-type="fig"}; **(C)** Same as Fig 4A., except data are from tile 3 in [Fig 2](#pone.0221519.g002){ref-type="fig"}.](pone.0221519.g004){#pone.0221519.g004}

Beginning with TNF and continuing through SLC9A1 on the [Fig 4C](#pone.0221519.g004){ref-type="fig"} heat map are 17 candidate genes ("Group 2") which, compared to the previous 19 candidate genes, reciprocally correlate with global genes (negatively correlated in the bottom part of the map and positively in the mid-upper region). Eight of these 17 were concordant, with 6 downregulated. This gene cluster contains 3 cytokines (TNF, IL1B and IL6), the thyroid hormone receptor THRA1, and several β~1~-adrenergically regulated genes (ADRBK1, MYH6, GNAI2, MYL4, HK2, CPT-1 and SLC9A1). Finally, the third region on the map beginning with PDK4 and proceeding through a total of 11 genes does not contain any obvious clustering of correlated mRNAs, similar to a 3 gene (ADCY5, CASQ2, MYL2) transition area between the two other regions. Of this total of 14 genes without correlative changes in expression, 4 (and CSRP3) were concordant, all downregulated. NPPA, NPPB, and ACTA1 are regulated by β~1~ adrenergic signaling. The other 7 members of this group consist of 3 metabolic genes (the β~1~-adrenergically regulated PDK4, PDHX and the reference gene GAPDH, 2 contractile proteins (TNNT2, TNNC1), and 2 neurohormonal genes (EDN1, AGT)).

Discussion {#sec032}
==========

We used cross-platform concordance of gene expression changes as a method of increasing the reliability of detecting biologically meaningful molecular changes associated with reverse remodeling in an idiopathic dilated cardiomyopathy study population. Cross-platform concordance has been widely used as a method to validate measurement methodologies \[[@pone.0221519.ref017]--[@pone.0221519.ref019],[@pone.0221519.ref022],[@pone.0221519.ref023]\], but in model systems it is also correlated with biologic and/or therapeutic signals \[[@pone.0221519.ref022],[@pone.0221519.ref032]--[@pone.0221519.ref034]\]. The use of cross-platform concordance was validated through a highly statistically significant relationship of concordant candidate gene changes with progressive reverse remodeling. We then extended the use of concordant gene expression changes to pathway analyses, which revealed both expected and unexpected results.

Cross-platform concordance of changes in gene expression {#sec033}
--------------------------------------------------------

C~cpT~ values, a standard measurement of expression change concordance, were in the 60% range for RT-qPCR and microarray measurements of candidate genes in the 47 patient *A-S* cohort, for both R and R/NR analyses. For the smaller (n = 12) *S-R* cohort that exhibited a greater degree of reverse remodeling, C~cpT~ values were somewhat lower, particularly in the R analysis on 2 platform comparisons that included microarray data. The lower C~cpT~ values in the *S-R* cohort likely reflect the difference in statistical power between the larger and smaller cohorts, plus possibly somewhat lesser accuracy of transcript detection by microarray compared to RT-qPCR or RNA-Seq.

In contrast to candidate genes in the *A-S* cohort, concordance of changes for global genes as assessed by microarray and RNA-Seq in the *S-R* cohort were extremely low in the change from baseline R analysis, with a C~cpT~ of 2.4%. However, the microarray/RNA-Seq C~cpT~ for candidate genes in the S-R cohort was 0%, suggesting that the smaller sample size *S-R* cohort was ill-suited for the R analysis. The R/NR analysis C~cpT~ for global gene expression was much higher, 17.5%, but lower than the counterpart C~cpT~ microarray/RNA-Seq value for candidate genes (38%, P \<0.036). These data emphasize the value of comparing R vs. NR changes (R/NR analysis), with the implication that an *in situ* myocardial gene expression study needs to be large enough to generate both reverse remodeling responders and nonresponders. In addition, the data support an expectedly higher concordance for candidate genes, which are enriched for genes likely to change expression in reverse remodeling. The larger global gene C~cpT~ for R/NR vs. R also supports the use of the R/NR analysis in pathway generation.

Cross-cohort concordance of changes in gene expression {#sec034}
------------------------------------------------------

Cross-cohort concordance, C~ccT~, was measured in data generated by a single platform in a manner analogous to inter-platform concordance. For candidate gene mRNAs measured by RT-qPCR the *A-S* cohort tended to have (p = 0.059 in the R analysis) or had (p \<0.01 in the R/NR analysis) more concordant changes, again indicating that the larger, *A-S* cohort had a statistical advantage that was not compensated by the greater degree of reverse remodeling in *S-R*. However, the *A-S*/*S-R* C~ccT~ of 56% in R and 25% in R/NR ([Table 5](#pone.0221519.t005){ref-type="table"}) supports comparability of the *S-R* and *A-S* cohorts, not surprising since *S-R* is a subset of *A-S*.

In *A-S* and *S-R* changes in expression of global genes was assessed by microarray. In the R analysis the *A-S* cohort yielded proportionally more statistically significant changes than in *S-R* (by 41%), whereas in the R/NR analysis the number of changes was nearly equal in the 2 cohorts, with fewer than half the number of changes in both *A-S* and *S-R*. The C~ccT~ for the R analysis was extremely low, 1.9%. In contrast, the C~ccT~ for R/NR was markedly higher, 42%, and within the range for R or R/NR C~ccT~ for candidate genes. The basis for the marked difference in C~ccT~ values was an R/NR vs. R increase in concordant genes by 7.7 fold and a decrease in the number of either-cohort changed genes by 2.8 fold, with corresponding implied reductions in both Type 2 and Type 1 error in the R/NR analysis. These data provide support for the validity of the *S-R* cohort as representative of global gene expression changes in *A-S*, but only for an R/NR analysis.

Biologic significance of platform concordance for gene expression changes {#sec035}
-------------------------------------------------------------------------

In the *A-S* cohort an analysis of platform concordance of changes in gene expression by degree of LVEF change indicated that most of the changes from baseline in the 1^st^ LVEF tertile, comprised entirely of Nonresponders, were non-concordant, and therefore likely to be false positives. In contrast, in patients undergoing reverse remodeling (tertiles 2 and 3) concordance was directly related to the degree of LVEF improvement and reached 59% in tile 3, where the increase in LVEF was by 29.6 absolute %. Candidate gene change analysis in the *S-R* cohort also provided support for the biologic significance of concordance. Two platform C~cpT~ exhibited a strong trend for an increase from NR to R to R/NR, reaching a value in R/NR (58%) that was quite similar to the *A-S* R/NR value of 62% despite the lower power of the *S-R* cohort. A straightforward interpretation of these data is that when comparing organ phenotypes, platform concordance for gene expression measurements is directly related to the degree of phenotypic change; that is, concordant changes have biologic meaning.

Gene network/signaling pathway analyses for concordant *S-R* gene expression changes in microarray and RNA-Seq {#sec036}
--------------------------------------------------------------------------------------------------------------

The demonstration of an acceptable degree of platform and cohort concordance for the R/NR analysis in *S-R* created the opportunity to perform a network analysis, for purposes of hypothesis generation. In this dataset downregulation exceeded upregulation, and the biologic categories of gene changes were unsurprisingly led by the growth/hypertrophy, cell homeostasis, fibroblast/extracellular matrix and extracellular to intracellular signaling categories. These changes are all consistent with reverse remodeling with inactivation of genes involved in myocyte and interstitial cell growth.

Despite all study subjects receiving high doses of β-blocking agents, cardiac β-adrenergic signaling and protein kinase A signaling had positive z-scores. All study subjects were receiving target/guideline recommended doses of metoprolol succinate or carvedilol that produce high levels of blockade of β~1~-adrenergic receptors, and both agents have been shown to reverse adrenergically-mediated desensitization changes in failing hearts \[[@pone.0221519.ref035],[@pone.0221519.ref036]\]. Although the low mRNA abundance ADRB1 gene was not concordantly upregulated in the R/NR global gene expression analysis in *S-R* ([Table 3](#pone.0221519.t003){ref-type="table"}), it was by RT-qPCR in the R/NR analysis in *A-S* ([Table 1](#pone.0221519.t001){ref-type="table"}), by PCR or RNA-Seq R analysis in *S-R* ([Table 2](#pone.0221519.t002){ref-type="table"}), and by RNA-Seq in the R/NR analysis in *S-R* ([Table 2](#pone.0221519.t002){ref-type="table"}). ADRB2 was concordantly upregulated in *A-S* R/NR ([Table 1](#pone.0221519.t001){ref-type="table"}). Restoration of β-receptor signaling could have produced a net activation of downstream cAMP/PKA and calcium signaling via receptor constitutive activity or by adrenergic signaling intermittently overriding β-blockade. The cAMP/PKA canonical pathway contained 3 upregulated and 5 downregulated genes whose protein products have been shown to regulate cAMP levels or be modifiable by PKA phosphorylation. The canonical calcium signaling pathway featured upregulation of ATP2A2 (SR Ca^2+^ ATPase) downregulation of CASQ1 and CASQ2, the respective minor and major abundance calsequestrins expressed in the heart, and the calcium regulated contractile proteins MYL3, TNNT1 and TPM3. However, expression changes of other modulators of Ca^2+^ signaling in the heart were not included in the Ingenuity cluster, such as upregulation of the phosphatase 1 inhibitor PPP1R1A that would be expected to promote SR Ca^2+^ uptake and release by inhibiting phospholamban dephosphorylation. The activation or improvement in calcium signaling as the LV reverse remodels is supported by work in model systems \[[@pone.0221519.ref037]\].

There were also some interesting findings within the IPA canonical pathway analysis involving noncandidate genes that have not been previously reported in ventricular reverse remodeling in the human heart. Phosphoinositide signaling occupied 3 of the top 4 negative z score or inhibited pathways, 2 pathways containing numerous collagen transcripts were in the first 5 inhibited pathways, and Gα12/13 signaling was the second highest ranked of only 6 activated pathways. None of these pathways had z-scores with absolute values of \>2.0, so the findings are only hypothesis generating. Neither phosphoinositide or Gα12/13 signaling have been prominently identified in our \[[@pone.0221519.ref038]\] or other large scale \[[@pone.0221519.ref039]\] human myocardial remodeling gene expression studies, but the role of phosphoinositide signaling in pathologic hypertrophy and heart failure have been reported in numerous animal model studies \[[@pone.0221519.ref040]--[@pone.0221519.ref045]\]. Importantly, the PI3 kinase signaling pathway interacts with β~1~-adrenergic receptor expression and signaling \[[@pone.0221519.ref046]\], providing biologic plausibility for phosphoinositide pathway gene expression changes in that in adult rat cardiac myocytes β~1~-adrenergic receptor signaling leads to increased PI3K activity which then attenuates adrenergically mediated positive inotropic effects \[[@pone.0221519.ref046]\]. Similarly, β~1~-adrenergic receptor signaling has been shown to be a powerful mediator of fibrosis and other forms of extracellular matrix deposition in model systems \[[@pone.0221519.ref040],[@pone.0221519.ref047]--[@pone.0221519.ref050]\], but generally has not been considered a major therapeutic target of β-blockers in reverse remodeling. In the human heart \[[@pone.0221519.ref051]\] Gα12/13 transduces hypertrophic signals \[[@pone.0221519.ref052]\] for a number of non-β-adrenergic receptors such as endothelin-ET~A~ and angiotensin II AT~1~, and Gα12 mRNA expression is upregulated in the transition of pathologic hypertrophy to failure in the Dahl salt-sensitive rat model \[[@pone.0221519.ref052]\]. Despite this evidence that upregulation of Gα12/13 signal transduction can produce pathologic hypertrophy, several lines of evidence indicate that this signaling module may be cardioprotective \[[@pone.0221519.ref053],[@pone.0221519.ref054]\], and the contractile protein member (MYL3) is an \"adult\" gene within the fetal/adult expression paradigm \[[@pone.0221519.ref055]\] that regulates contractility \[[@pone.0221519.ref056]\].

Of note is that the IPA canonical pathway Cardiac Hypertrophy Signaling had a neutral activation z-score, with an overlapping P value of--log 1.82 (0.015) ([S7 Table](#pone.0221519.s009){ref-type="supplementary-material"}), despite the biologic category of Growth/hypertrophy regulation having 21 downregulated vs. 8 upregulated genes ([S3 Table](#pone.0221519.s005){ref-type="supplementary-material"}). This discrepancy is likely due to differences in how the two classification instruments are constructed; the biologic category ([S3 Table](#pone.0221519.s005){ref-type="supplementary-material"}) placed genes with demonstrated changes into groupings based on curation of the current myocardium relevant literature and NCBI websites, while the IPA inserted the same changes into a proprietary algorithm where genes are assigned to signaling modules.

Correlation of candidate with global gene changes in the *A-S* cohort {#sec037}
---------------------------------------------------------------------

In a correlation analysis between changes in candidate and global gene expression in the *A-S* cohort two potential patterns were identified that may be candidates for extensive gene regulation networks. One group (Group 1) had in common β~1~-AR gene signaling, for which there is considerable previous evidence \[[@pone.0221519.ref008],[@pone.0221519.ref057]\]. Group 2 included GNAI2, which regulates multiple signaling pathways involved in hypertrophy including LPA signaling \[[@pone.0221519.ref029],[@pone.0221519.ref030]\]. Both these potential networks, which exhibited reciprocal regulation, appeared to contain an extensive number of genes likely numbering in at least the hundreds based on the size of the area on the heat map and assuming that only a small percentage (≤10%) of genes is imparting the color to the map. A third group of genes with no strong clustered correlations was also identified, with the natriuretic peptides NPPA/NPPB as the centerpiece.

Basis for the advantage of cross-platform concordance in human *in situ* studies of gene expression {#sec038}
---------------------------------------------------------------------------------------------------

We evaluated gene expression change concordance as a means to improve the likelihood of biologic relevance of differential gene expression associated with reverse remodeling of failing, eccentrically hypertrophied human LVs. In terms of failure to achieve change concordance, both technical/methodological and biological causes are possible. For cross-platform concordance in the *A-S* cohort the majority of the non-concordance was presumably technical/methodological related, most likely related platform sensitivity and specificity of transcript identification and quantitation. However, endomyocardial biopsy sampling and RNA extraction variability would also fall within this category. For biologic sources of non-concordance, within the *A-S* R and NR groups (i.e. the components of the R/NR analysis) variance in degrees of remodeling and the relationship between remodeling and change in individual patient gene expression are also potential sources. For the much smaller sample size *S-R* cohort, both types of causes would be accentuated, and for the cross-cohort comparisons biologic causes would be a relatively greater contributor to nonconcordance since the responder phenotypes were quantitatively different.

All 3 methodologies used for cross-platform measurements have been extensively validated against each other \[[@pone.0221519.ref011]--[@pone.0221519.ref013],[@pone.0221519.ref022],[@pone.0221519.ref023]\], and with the possible exception of microarray in the R analysis in the *S-R* cohort, they performed similarly in this study. Compared to RT-qPCR and RNA-Seq microarray may have been at some disadvantage for low abundance mRNAs, but nevertheless was able to detect changes in some of them such as β-adrenergic receptors. TaqMan or Real Time qPCR has long been considered the "gold standard" for RNA quantitation but is impractical for measurement of global gene expression. Microarrays revolutionized the measurement of genome-wide transcriptomics, and held sway as the dominant methodology for over a decade \[[@pone.0221519.ref058]\]. Due to its flexibility for measuring multiple RNA gene products and now being cost-effective, RNA-Seq has replaced microarrays as the most widely used methodology for identifying and quantifying multiple RNA species \[[@pone.0221519.ref059]\].

As the methods for quantifying mRNA abundance are different for the 3 technologies, the statistical probability of achieving a P \<0.05 with the same directional change across 2 platforms is 0.05^2^/2 or 0.00125. Therefore, some of the value of cross-platform concordance can be attributed to statistical stringency. However, the utility of a 2^nd^, confirming measurement in real time by different methodology likely confers value for concordance beyond setting a lower P value to minimize false discovery rate (FDR). In gene expression experiments that include large numbers of measurements problems with controlling FDR without having an adverse effect on sensitivity are well known \[[@pone.0221519.ref060],[@pone.0221519.ref061]\], and contemporaneous measures of cross-platform concordance can be viewed as an alternative to using stringent P values or FDR adjusted q values to lower Type I error.

Limitations {#sec039}
-----------

The data presented and the conclusions reached apply only to a SAMGE-PC design and may not be applicable to cross-sectional studies, as the general advantages of longitudinal, repeated measures designs \[[@pone.0221519.ref062]\] certainly apply to gene expression studies \[[@pone.0221519.ref016]\]. The study used endomyocardial biopsies taken from the distal RV septum as starting material for RNA extraction. Although the septum is an interventricular shared wall whose gene expression tracks with LV \[[@pone.0221519.ref006],[@pone.0221519.ref008],[@pone.0221519.ref063]\] and RV \[[@pone.0221519.ref063]\] remodeling, tissue from the right side of the septum may not be as representative of LV molecular remodeling as LV biopsies. However, in this study only the LV demonstrated statistically significant reverse remodeling, and therefore the observed changes in gene expression are likely to be representative of LV biologic effects. For cost reasons we confined RNA-Seq to a 12 patient Super-Responder subcohort, and ideally all 47 patients would have had these measurements. The *S-R* subcohort was a subset of the larger *A-S* cohort, and therefore was not independent of the parent population. Finally, since RNA-Seq has become the favored method of measuring transcript abundance investigators may be reluctant to add another platform to their study design, and it is not clear if performing two separate RNA preparation and sequencing runs could substitute for mRNA abundance determination in a completely separate platform. Nevertheless, a cross-platform concordance design performed contemporaneously as opposed to for post hoc confirmation should be considered for *in situ* human gene expression studies, where starting material is limited and repeating experiments is untenable.

Conclusions {#sec040}
===========

For measurement of myocardial gene expression in sequential studies that include a baseline control value, among RT-qPCR, microarray and RNA-Seq methods there was no convincing advantage of one platform over another. However, for measurements of both candidate and global gene expression the use of 2 platforms had an advantage over a single platform, allowing for the use of cross-platform concordance as a more robust measure of biologically-related changes in gene expression. The basis for the 2-platform concordance advantage is likely related to the derived alpha calculation of 0.00125, but also to the requirement that independent measurement technologies yield conventional significance levels. Measurement concordance is more valuable for global gene expression, where the false discovery rate is higher than for candidate genes preselected for potential involvement in the remodeling process, but concordance also adds value in a candidate/hypothesis driven setting. Multiple lines of evidence favored the use of the larger but less reverse remodeled *A-S* cohort over the smaller, more improved phenotype *S-R* subcohort, and global gene expression measurements were only available in *S-R*. Nevertheless, a 42% C~ccT~ between *A-S* and *S-R* for global R/NR changes indicated that for this analysis the *S-R* subcohort was representative of the *A-S* cohort. Finally, both IPA and biologic category analyses support an improvement in calcium signaling as the major gene expression correlate of reverse remodeling, consistent with the improvement in systolic function that is associated with improved LVEF as well as previous work in model systems.

IPA and Superheat map investigation of concordant gene expression changes in the R/NR global gene expression analysis in *S-R* identified the likely involvement of unexpected canonical pathways in the reverse remodeling process, as well as potentially large networks involving β-AR and possibly GNAI2 regulation.

The data support the advantage of sequential measurements of gene expression before and after organ phenotype modification, particularly if phenotype responders can be compared to nonresponders in an R/NR design.

Measuring human ventricular myocardial gene expression in situ by serial endomyocardial biopsy remains a research tool only, but has the potential, particularly by employing multi-platform measurements in larger cohorts undergoing reverse remodeling, to identify novel mechanisms important in myocardial failure and hypertrophy.
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